Scarica l'app Stockscreener
1.12
0.00%
0.00
Dopo l'orario di chiusura:
1.10
-0.02
-1.79%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCLI Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.12
Aprire:
$1.13
Volume 24 ore:
1.16M
Relative Volume:
1.01
Capitalizzazione di mercato:
$8.89M
Reddito:
-
Utile/perdita netta:
$-16.63M
Rapporto P/E:
-2.6047
EPS:
-0.43
Flusso di cassa netto:
$-21.84M
1 W Prestazione:
+3.70%
1M Prestazione:
+3.23%
6M Prestazione:
-35.63%
1 anno Prestazione:
-85.50%
Intervallo 1D:
$1.05
$1.22
Intervallo di 1 settimana:
$1.00
$1.22
Portata 52W:
$0.7233
$8.0985
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Nome
Brainstorm Cell Therapeutics Inc
Settore
Industria
Telefono
201-488-0460
Indirizzo
1325 AVENUE OF AMERICAS, NEW YORK, NY
Confronta BCLI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
1.12 | 8.57M | 0 | -16.63M | -21.84M | -0.43 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-02-04 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-11-17 | Downgrade | Maxim Group | Buy → Hold |
| 2016-12-19 | Reiterato | Maxim Group | Buy |
| 2015-12-22 | Reiterato | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Borsa (BCLI) Ultime notizie
What is Zacks Small Cap’s Estimate for BCLI FY2025 Earnings? - Defense World
Q2 Earnings Estimate for BCLI Issued By Zacks Small Cap - Defense World
BrainStorm Cell Therapeutics and Minaris partner on manufacturing NurOwn for trial - Yahoo Finance
BrainStorm partners with Minaris for ALS therapy trial By Investing.com - Investing.com South Africa
BCLI: Receives Regulatory Clearance to Initiate Phase 3b ALS Trial… - Yahoo Finance
BrainStorm partners with Minaris for ALS therapy trial - Investing.com Australia
BrainStorm Cell Therapeutics (BCLI) Partners with Minaris for Nu - GuruFocus
BrainStorm Cell Therapeutics (BCLI) Partners with Minaris for NurOwn Manufacturing | BCLI Stock News - GuruFocus
BrainStorm Accelerates NurOwn ALS Treatment Development Through Major Manufacturing Deal with Minaris - Stock Titan
INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Brainstorm Cell Lawsuit – BCLI - ACCESS Newswire
FDA clears Phase 3b trial of NurOwn for ALS - ALS News Today
Gene And Cell Therapies Targeting Cns Disorders Market in 2025 - openPR.com
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com - Defense World
Brainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plans - MSN
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2025 Earnings Call Transcript - Insider Monkey
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
What Did We Note About Insider Trading At Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI)? - Stocksregister
FDA grants clearance to BrainStorm’s Phase IIIb trial of ALS treatment - Yahoo Finance
Brainstorm Cell Therapeutics Reports Q1 2025 Financials - TipRanks
BrainStorm advances ALS treatment with FDA trial nod By Investing.com - Investing.com South Africa
BrainStorm advances ALS treatment with FDA trial nod - Investing.com Australia
Sector Update: Health Care Stocks Advance Monday Afternoon - marketscreener.com
Top Midday Gainers - marketscreener.com
BrainStorm (BCLI) Options Delisting Announced | BCLI Stock News - GuruFocus
Brainstorm Cell Therapeutics (BCLI) Advances Phase 3b ALS Trial - GuruFocus
Earnings call transcript: BrainStorm Cell Therapeutics Q1 2025 sees stock surge after trial updates - Investing.com Nigeria
Micro Cap Bid Up Aggressively On FDA Clearance Announcement - The Globe and Mail
Transcript : Brainstorm Cell Therapeutics Inc., Q1 2025 Earnings Call, May 19, 2025 - marketscreener.com
BrainStorm (BCLI) Receives FDA Green Light for NurOwn Phase 3b A - GuruFocus
BrainStorm Cleared by FDA to Begin Phase 3b Trial of NurOwn for ALS - marketscreener.com
Breaking ALS Treatment News: FDA Gives Green Light to BrainStorm's Crucial Phase 3b NurOwn Trial - Stock Titan
SEC Form DEFA14A filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - StreetInsider
BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 - PR Newswire
BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 - The Malaysian Reserve
SEC Form 10-Q filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
Brainstorm Cell Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BrainStorm's NurOwn ALS Treatment Takes Major Step Forward: FDA Amendment Filed, Trial Sites Ready - Stock Titan
BrainStorm Reschedules First Quarter 2025 Financial Results Rele - GuruFocus
BrainStorm Cell Therapeutics Moves Q1 2025 Earnings Release to Today, Full Management Team to Host May 19 Call - Stock Titan
StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Brainstorm Cell Therapeutics (BCLI) to Release Earnings on Thursday - Defense World
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2024 Earnings Call Transcript - MSN
Stem Cell Therapy Market 2025: Technical Signs Point Higher Growth Levels - newstrail.com
SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit - Nasdaq
BrainStorm's ALS Treatment Breakthrough: New Biomarker Data Shows Promise as FDA-Approved Trial Approaches - Stock Titan
Geode Capital Management LLC Sells 630,315 Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Defense World
5 Best Stem Cell Companies to Invest In (May 2025) - Securities.io
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Brainstorm Cell LawsuitBCLI - ACCESS Newswire
Brainstorm Cell Therapeutics Inc Azioni (BCLI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):